0000897069-14-000470.txt : 20141119 0000897069-14-000470.hdr.sgml : 20141119 20141119120532 ACCESSION NUMBER: 0000897069-14-000470 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20141119 DATE AS OF CHANGE: 20141119 EFFECTIVENESS DATE: 20141119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Romark Laboratories, L.C. CENTRAL INDEX KEY: 0001470263 IRS NUMBER: 593276909 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-219719 FILM NUMBER: 141234237 BUSINESS ADDRESS: STREET 1: 3000 BAYPORT DRIVE STREET 2: SUITE 200 CITY: TAMPA STATE: FL ZIP: 33607 BUSINESS PHONE: 813-282-8544 MAIL ADDRESS: STREET 1: 3000 BAYPORT DRIVE STREET 2: SUITE 200 CITY: TAMPA STATE: FL ZIP: 33607 D/A 1 primary_doc.xml X0707 D/A LIVE 0001470263 Romark Laboratories, L.C. 3000 BAYPORT DRIVE SUITE 200 TAMPA FL FLORIDA 33607 813-282-8544 FLORIDA None None Limited Liability Company true Jean Francois Rossignol 3000 Bayport Drive Suite 200 Tampa FL FLORIDA 33607 Executive Officer Director Marc S. Ayers 3000 Bayport Drive Suite 200 Tampa FL FLORIDA 33607 Executive Officer Director Celine E. Rossignol 3000 Bayport Drive Suite 200 Tampa FL FLORIDA 33607 Executive Officer Brian Schnieders 3000 Bayport Drive Suite 200 Tampa FL FLORIDA 33607 Executive Officer W. Seymour Holt 3000 Bayport Drive Suite 200 Tampa FL FLORIDA 33607 Director W. Andrew Krusen, Jr. 3000 Bayport Drive Suite 200 Tampa FL FLORIDA 33607 Director Kurt Frahn 3000 Bayport Drive Suite 200 Tampa FL FLORIDA 33607 Executive Officer Pharmaceuticals Decline to Disclose 06b true 0000897069-14-000317 2014-05-27 false true true true false 100000 International Assets Advisory, LLC 10645 None None 300 South Orange Avenue Suite 1100 Orlando FL FLORIDA 32801 All States false Source Capital Group, Inc. 36719 None None 276 Post Road West Westport CT CONNECTICUT 06880 All States false WFG Investments, Inc. 22704 None None 2711 N. Haskell Avenue Suite 2900 Dallas TX TEXAS 75204 AL ALABAMA AK ALASKA AZ ARIZONA AR ARKANSAS CA CALIFORNIA CO COLORADO CT CONNECTICUT DE DELAWARE DC DISTRICT OF COLUMBIA FL FLORIDA GA GEORGIA HI HAWAII ID IDAHO IL ILLINOIS IN INDIANA IA IOWA KS KANSAS KY KENTUCKY LA LOUISIANA MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA MS MISSISSIPPI MO MISSOURI MT MONTANA NE NEBRASKA NV NEVADA NH NEW HAMPSHIRE NJ NEW JERSEY NM NEW MEXICO NY NEW YORK NC NORTH CAROLINA ND NORTH DAKOTA OH OHIO OK OKLAHOMA OR OREGON PA PENNSYLVANIA RI RHODE ISLAND SC SOUTH CAROLINA SD SOUTH DAKOTA TN TENNESSEE TX TEXAS UT UTAH VT VERMONT VA VIRGINIA WA WASHINGTON WV WEST VIRGINIA WI WISCONSIN WY WYOMING false 15000000 10750100 4249900 false 112 1500000 true 0 10% of the gross proceeds raised, a non-accountable expense allowance in an amount equal to 1.0% of gross proceeds, reimbursement of reasonable out-of-pocket expenses and a Warrant to purchase Common Units equal to 15% of the number of Class C Units issue 0 false Romark Laboratories, L.C. Kurt Frahn Kurt Frahn Chief Financial Officer 2014-11-17